The Readout Loud

291: The plight of the VC, Gilead's latest setback, & more M&A

Jan 25, 2024
Biotech's downturn affects startups and venture capitalists. Gilead struggles to become an oncology company. A major pharma firm acquires a biotech company. Challenges faced by VCs in funding biotech. Gilead focuses on CAR-T therapy and its acquisition strategies.
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 3min
2
Favorite movies, Oppenheimer, and a biotech M&A deal
02:51 • 2min
3
Spin-off Companies in Biotech Acquisitions
04:23 • 7min
4
Challenges for VCs in Biotech Investment
11:36 • 9min
5
Gilead's Strategy in Oncology and CAR-T Therapy
20:44 • 10min